

## **Chronic Idiopathic Urticaria - Epidemiology Forecast** to 2032

https://marketpublishers.com/r/C3422B39E40DEN.html

Date: January 2022

Pages: 60

Price: US\$ 3,950.00 (Single User License)

ID: C3422B39E40DEN

## **Abstracts**

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Chronic Idiopathic Urticaria - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Chronic Idiopathic Urticaria epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

The United States

EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Japan

Study Period: 2019-2032

Chronic Idiopathic Urticaria Understanding

The DelveInsight Chronic Idiopathic Urticaria epidemiology report gives a thorough understanding of the Chronic Idiopathic Urticaria by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Chronic Idiopathic Urticaria in the US, Europe, and Japan. The report covers the detailed information of the Chronic Idiopathic Urticaria epidemiology scenario in seven major countries (US, EU5, and Japan).



#### Chronic Idiopathic Urticaria Epidemiology Perspective by DelveInsight

The Chronic Idiopathic Urticaria epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Chronic Idiopathic Urticaria epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Chronic Idiopathic Urticaria epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Chronic Idiopathic Urticaria Detailed Epidemiology Segmentation

The Chronic Idiopathic Urticaria epidemiology covered in the report provides historical as well as forecasted Chronic Idiopathic Urticaria epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Chronic Idiopathic Urticaria report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

#### Scope of the Report

The Chronic Idiopathic Urticaria report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

The Chronic Idiopathic Urticaria Epidemiology Report and Model provide an overview of the global trends of Chronic Idiopathic Urticaria in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)

The report provides insight into the historical and forecasted patient pool of Chronic Idiopathic Urticaria in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan

The report helps recognize the growth opportunities in the 7MM for the patient



population

The report assesses the disease risk and burden and highlights the unmet needs of Chronic Idiopathic Urticaria

The report provides the segmentation of the Chronic Idiopathic Urticaria epidemiology

## Report Highlights

11-year Forecast of Chronic Idiopathic Urticaria epidemiology

7MM Coverage

Prevalent and Diagnosed Cases of Chronic Idiopathic Urticaria

Cases of Chronic Idiopathic Urticaria by Mutation Types

Chronic Idiopathic Urticaria Cases associated with Clinical Manifestations

#### **KOL** views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

#### **Key Questions Answered**

What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Chronic Idiopathic Urticaria?

What are the key findings pertaining to the Chronic Idiopathic Urticaria epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?

What would be the total number of patients of Chronic Idiopathic Urticaria across



the 7MM during the forecast period (2019-2032)?

Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?

At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?

What is the disease risk, burden and unmet needs of Chronic Idiopathic Urticaria?

What are the currently available treatments of Chronic Idiopathic Urticaria?

### Reasons to buy

The Chronic Idiopathic Urticaria Epidemiology report will allow the user to -

Develop business strategies by understanding the trends shaping and driving the global Chronic Idiopathic Urticaria market

Quantify patient populations in the global Chronic Idiopathic Urticaria market to improve product design, pricing, and launch plans

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Chronic Idiopathic Urticaria therapeutics in each of the markets covered

Understand the magnitude of Chronic Idiopathic Urticaria population by its epidemiology

The Chronic Idiopathic Urticaria Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

#### Key Assessments



Patient Segmentation

Disease Risk & Burden

Risk of disease by the segmentation

Factors driving growth in a specific patient population



## **Contents**

#### 1. KEY INSIGHTS

#### 2. EXECUTIVE SUMMARY OF CHRONIC IDIOPATHIC URTICARIA

#### 3. CHRONIC IDIOPATHIC URTICARIA: DISEASE BACKGROUND AND OVERVIEW

- 3.1. Introduction
- 3.2. Sign and Symptoms
- 3.3. Pathophysiology
- 3.4. Risk Factors
- 3.5. Diagnosis

#### 4. PATIENT JOURNEY

#### 5. EPIDEMIOLOGY AND PATIENT POPULATION

- 5.1. Epidemiology Key Findings
- 5.2. Assumptions and Rationale: 7MM
- 5.3. Epidemiology Scenario: 7MM
  - 5.3.1. Chronic Idiopathic Urticaria Epidemiology Scenario in the 7MM (2019- 2032)
- 5.4. United States Epidemiology
- 5.4.1. Chronic Idiopathic Urticaria Epidemiology Scenario in the United States (2019-2032)
- 5.5. EU-5 Country-wise Epidemiology
  - 5.5.1. Germany Epidemiology
  - 5.5.1.1. Chronic Idiopathic Urticaria Epidemiology Scenario in Germany (2019- 2032)
  - 5.5.2. France Epidemiology
    - 5.5.2.1. Chronic Idiopathic Urticaria Epidemiology Scenario in France (2019-2032)
  - 5.5.3. Italy Epidemiology
  - 5.5.3.1. Chronic Idiopathic Urticaria Epidemiology Scenario in Italy (2019- 2032)
  - 5.5.4. Spain Epidemiology
  - 5.5.4.1. Chronic Idiopathic Urticaria Epidemiology Scenario in Spain (2019- 2032)
  - 5.5.5. United Kingdom Epidemiology
- 5.5.5.1. Chronic Idiopathic Urticaria Epidemiology Scenario in the United Kingdom (2019-2032)
- 5.6. Japan Epidemiology
  - 5.6.1. Chronic Idiopathic Urticaria Epidemiology Scenario in Japan (2019-2032)



# 6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

- 6.1. Chronic Idiopathic Urticaria Treatment and Management
- 6.2. Chronic Idiopathic Urticaria Treatment Algorithm
- 7. KOL VIEWS
- 8. UNMET NEEDS
- 9. APPENDIX
- 9.1. Bibliography
- 9.2. Report Methodology
- 10. DELVEINSIGHT CAPABILITIES
- 11. DISCLAIMER
- 12. ABOUT DELVEINSIGHT

\*The table of contents is not exhaustive; will be provided in the final report



## **List Of Tables**

#### LIST OF TABLES

List of Table:

Table 1: Chronic Idiopathic Urticaria Epidemiology in 7MM (2019-2032)

Table 2: Chronic Idiopathic Urticaria Diagnosed and Treatable Cases in 7MM (2019-2032)

Table 3: Chronic Idiopathic Urticaria Epidemiology in the United States (2019-2032)

Table 4: Chronic Idiopathic Urticaria Diagnosed and Treatable Cases in the United States (2019-2032)

Table 5: Chronic Idiopathic Urticaria Epidemiology in Germany (2019-2032)

Table 6: Chronic Idiopathic Urticaria Diagnosed and Treatable Cases in Germany (2019-2032)

Table 7: Chronic Idiopathic Urticaria Epidemiology in France (2019-2032)

Table 8: Chronic Idiopathic Urticaria Diagnosed and Treatable Cases in France (2019-2032)

Table 9: Chronic Idiopathic Urticaria Epidemiology in Italy (2019-2032)

Table 10: Chronic Idiopathic Urticaria Diagnosed and Treatable Cases in Italy (2019-2032)

Table 11: Chronic Idiopathic Urticaria Epidemiology in Spain (2019-2032)

Table 12: Chronic Idiopathic Urticaria Diagnosed and Treatable Cases in Spain (2019-2032)

Table 13: Chronic Idiopathic Urticaria Epidemiology in the United Kingdom (2019-2032)

Table 14: Chronic Idiopathic Urticaria Diagnosed and Treatable Cases in the United Kingdom (2019-2032)

Table 15: Chronic Idiopathic Urticaria Epidemiology in Japan (2019-2032)

Table 16: Chronic Idiopathic Urticaria Diagnosed and Treatable Cases in Japan (2019-2032)



## **List Of Figures**

#### LIST OF FIGURES

List of Figures

Figure 1 Chronic Idiopathic Urticaria Epidemiology in 7MM (2019-2032)

Figure 2 Chronic Idiopathic Urticaria Diagnosed and Treatable Cases in 7MM (2019-2032)

Figure 3 Chronic Idiopathic Urticaria Epidemiology in the United States (2019-2032)

Figure 4 Chronic Idiopathic Urticaria Diagnosed and Treatable Cases in the United States (2019-2032)

Figure 5 Chronic Idiopathic Urticaria Epidemiology in Germany (2019-2032)

Figure 6 Chronic Idiopathic Urticaria Diagnosed and Treatable Cases in Germany (2019-2032)

Figure 7 Chronic Idiopathic Urticaria Epidemiology in France (2019-2032)

Figure 8 Chronic Idiopathic Urticaria Diagnosed and Treatable Cases in France (2019-2032)

Figure 9 Chronic Idiopathic Urticaria Epidemiology in Italy (2019-2032)

Figure 10 Chronic Idiopathic Urticaria Diagnosed and Treatable Cases in Italy (2019-2032)

Figure 11 Chronic Idiopathic Urticaria Epidemiology in Spain (2019-2032)

Figure 12 Chronic Idiopathic Urticaria Diagnosed and Treatable Cases in Spain (2019-2032)

Figure 13 Chronic Idiopathic Urticaria Epidemiology in the United Kingdom (2019-2032)

Figure 14 Chronic Idiopathic Urticaria Diagnosed and Treatable Cases in the United Kingdom (2019-2032)

Figure 15 Chronic Idiopathic Urticaria Epidemiology in Japan (2019-2032)

Figure 16 Chronic Idiopathic Urticaria Diagnosed and Treatable Cases in Japan (2019-2032)

\*The table of contents is not exhaustive; will be provided in the final report



#### I would like to order

Product name: Chronic Idiopathic Urticaria - Epidemiology Forecast to 2032

Product link: <a href="https://marketpublishers.com/r/C3422B39E40DEN.html">https://marketpublishers.com/r/C3422B39E40DEN.html</a>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

## **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/C3422B39E40DEN.html">https://marketpublishers.com/r/C3422B39E40DEN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

& Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970